Blog

Chris Boshoff: Positive phase 3 results for Pfizer’s PD-1 inhibitor in high-risk NMIBC

Chris Boshoff/LinkedIn

Jan 13, 2025, 15:18

Chris Boshoff: Positive phase 3 results for Pfizer’s PD-1 inhibitor in high-risk NMIBC

Chris Boshoff, Chief Oncology Officer and President of Research and Development at Pfizer, shared a post on LinkedIn:

“I’m excited to share that we have announced positive event-free survival results from a Phase 3 trial with Pfizer’s PD-1 inhibitor in combination with BCG induction and maintenance therapy in patients with BCG-naïve, high-risk non-muscle invasive bladder cancer (NMIBC).

Learn more.

These results are potentially practice-changing, representing the first advance in therapy for BCG-naive, high-risk, non-muscle invasive cancer in over 30 years.

With these positive results, this is the first study for any PD-1 or PD-L1 inhibitor to show prolonged event-free survival for this patient population, when used in combination with BCG induction therapy with maintenance versus BCG alone.

These are also the first pivotal Phase 3 data for our PD-1 inhibitor, which was developed as a subcutaneous injection with a prefilled syringe and could help lower the treatment burden on both patients and healthcare systems, if approved.

At Pfizer, we are committed to developing new treatment options for patients with bladder cancer across the disease continuum. Thank you to all of the investigators, Pfizer colleagues, patients and their families who took part in this important trial.”

Proceed to the video attached to the post.

More posts featuring Chris Boshoff.

Chris Boshoff serves as Chief Oncology Officer and President of Research and Development at Pfizer and leads the company’s Oncology research and development organization.

Boshoff, formerly the founding Director of the University College London Cancer Institute, has published over 150 highly cited articles on cancer biology, tumor virology, and experimental cancer medicine.

Under his leadership, Pfizer has achieved numerous global approvals for cancer medicines and has developed various companion diagnostics for precision medicines.